US Patent

US11951213 — Synthetic progestogens and pharmaceutical compositions comprising the same

Method of Use · Assigned to Laboratorios Leon Farma SA · Expires 2031-06-28 · 5y remaining

Vulnerability score 81/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects synthetic progestogens, such as 6Î²,7Î²:15Î²,16Î²-Dimethylene-3-oxo-17Î±-pregn-4-ene-21,17-carbolactone, and methods of using them.

USPTO Abstract

Described herein are synthetic progestogens, such as 6Î²,7Î²:15Î²,16Î²-Dimethylene-3-oxo-17Î±-pregn-4-ene-21,17-carbolactone, as well as pharmaceutical compositions comprising the same. Also described are methods of use.

Drugs covered by this patent

Slynd (DROSPIRENONE) · Exeltis Usa Inc

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2553`	—	Slynd
`U-2553`	—	Slynd

Patent Metadata

Patent number: US11951213
Jurisdiction: US
Classification: Method of Use
Expires: 2031-06-28
Drug substance claim: No
Drug product claim: No
Assignee: Laboratorios Leon Farma SA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.